FDA on Monday is expected to name Kathleen Uhl, a veteran agency official who most recently served as the supervisory medical officer in FDA's Center for Drug Evaluation and Research, as director of the Office of Women's Health, the Washington Post reports (Kaufman, Washington Post, 11/21). Uhl will replace Susan Wood, who in September resigned from the agency in protest of its action to defer indefinitely a decision on Barr Laboratories' application for nonprescription sales of its emergency contraceptive Plan B. Wood, a biologist, had served as assistant FDA commissioner for women's health since 2000. Theresa Toigo, director of the agency's Office of Special Health Issues, currently is serving as acting director of women's health. Toigo was appointed shortly after the agency sent an e-mail notice to women's groups and others announcing the appointment to the post of Norris Alderson, the agency's associate commissioner for science, who has spent much of his career in FDA's Center for Veterinary Medicine (Kaiser Daily Reproductive Health Report, 9/20). Several groups protested Alderson's appointment, and later the agency announced that Toigo had been selected. According to the draft FDA release, Uhl began working as a medical reviewer at FDA in 1998 and later was named deputy division director and acting division director of the Office of Post-Marketing Drug Risk Assessment. Uhl has worked in laboratory and clinical research, clinical practice, drug application review, drug safety oversight and women's health issues. She also is a practicing physician at the Walter Reed Army Medical Center in Washington, D.C. Wood said Uhl "would be a good choice for the job," adding that she frequently has worked with Uhl and that "she is a long-standing advocate for women's health in the agency." Uhl is scheduled to take over the position in December (Washington Post, 11/21).